The Cardiff-based FemTech start-up exceeded its fundraising target to support its product roadmap.
"I do believe that our mutual Welsh affinity gives us that extra something; it’s a commonality that’s both unique and rare. So, thank you to the team at GlobalWelsh for bringing us together."
— Jolie Powell, Business consultant and angel investor
The financing round was led by Atomico with participation from several returning and new investors.
"The size of this Series B financing, especially this quickly after our Series A round last year, is an endorsement of the value of our platform and the pace at which we have developed. It allows us to scale our impact with the launch of our Rare Treatment Accelerator programme and to progress into clinical trials."
The funding round was led by Mercia to support pre-clinical testing and manufacturing as the company prepares for clinical trials.
"Our goal is to bring much-needed improvement to the lives of three million dialysis patients. This investment allows us to take a big step towards this, and we are delighted to have won the backing of a consortium of smart, well-funded investors."
Atomico led the Series A round with participation from Connect Ventures, Greycroft, Hoxton Ventures, and EXOR Seeds.
"The foundation of Kheiron’s approach to rigorous development and testing is to ensure reliably improved patient outcomes and safety by helping doctors in their daily practice,"
The financing round was led by Archangel Investors to support ongoing Phase IIa trials for its lead antibiotic.
"There remains a desperate need for novel treatments in our armoury to treat C. difficile infections. The work that MGB Biopharma is undertaking is both important and innovative and the results that have been achieved so far have been very encouraging."
— Sarah Hardy, Head of New Investments and Director